# A Study of the Safety and Efficacy of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis (MK-5592-069)

> **NCT01782131** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 585 (actual)

## Conditions studied

- Fungal Infections
- Invasive Pulmonary Aspergillosis

## Interventions

- **DRUG:** Posaconazole
- **DRUG:** Voriconazole
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01782131
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09-25
- **Primary completion:** 2019-07-10
- **Final completion:** 2019-09-10
- **Target enrollment:** 585 (ACTUAL)
- **Last updated:** 2024-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01782131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01782131, "A Study of the Safety and Efficacy of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis (MK-5592-069)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01782131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*